Shp2 inhibitors and uses thereof
AssigneeSYNBLia Therapeutics, Inc.
InventorsYinong Xie, Lee E. Babiss
Life of this patent
Estimating the term…
Abstract
Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.
Claims23
A compound represented by a formula:
- or a pharmaceutically acceptable salt thereof;
- wherein X is S;
- Ring A is an optionally substituted aryl having 6-10 ring carbon atoms, heteroaryl having 1-9 ring carbon atoms, or bicyclic ring system having 7-10 ring carbon atoms;
- Ring B is:
- and
- wherein RA and RB are independently H or C1-6 hydrocarbyl, or —N(RA)(RB) is an optionally substituted heterocyclic ring system, wherein the heterocyclic ring system is a mono-cyclic ring having 2-8 ring carbon atoms, 1-2 ring nitrogen atoms, 0-1 ring oxygen atom, and 0-1 ring sulfur atom;
- a bicyclic ring system having 5-12 ring carbon atoms, 1-2 ring nitrogen atoms, 0-1 ring oxygen atom, and 0-1 ring sulfur atom, or a tricyclic ring system having 8-16 ring carbon atoms, 1-2 ring nitrogen atoms, 0-1 ring oxygen atom, and 0-1 ring sulfur atom;
- and wherein the bicyclic ring system can be Spiro, fused, or bridged.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following compounds that is optionally substituted:
Dependencies are inferred from the claim text.